Swiss National Bank Has $2.60 Million Stake in Progyny, Inc. (NASDAQ:PGNY)

Swiss National Bank lessened its position in Progyny, Inc. (NASDAQ:PGNY) by 9.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 150,900 shares of the company’s stock after selling 16,400 shares during the period. Swiss National Bank owned 0.18% of Progyny worth $2,603,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Intech Investment Management LLC grew its holdings in shares of Progyny by 282.0% during the third quarter. Intech Investment Management LLC now owns 42,013 shares of the company’s stock worth $704,000 after purchasing an additional 31,014 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Progyny by 0.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 673,446 shares of the company’s stock worth $11,287,000 after acquiring an additional 4,007 shares during the last quarter. Quantbot Technologies LP acquired a new position in Progyny in the 3rd quarter valued at approximately $2,187,000. Public Sector Pension Investment Board bought a new position in shares of Progyny during the third quarter valued at $2,792,000. Finally, Edgestream Partners L.P. lifted its holdings in shares of Progyny by 72.7% during the third quarter. Edgestream Partners L.P. now owns 69,082 shares of the company’s stock worth $1,158,000 after purchasing an additional 29,074 shares during the period. Institutional investors and hedge funds own 94.93% of the company’s stock.

Progyny Stock Up 2.2 %

NASDAQ:PGNY opened at $22.31 on Friday. Progyny, Inc. has a twelve month low of $13.39 and a twelve month high of $38.98. The company has a fifty day moving average of $22.05 and a 200-day moving average of $18.58. The firm has a market capitalization of $1.91 billion, a P/E ratio of 38.47, a P/E/G ratio of 2.39 and a beta of 1.41.

Analysts Set New Price Targets

Several brokerages recently issued reports on PGNY. JPMorgan Chase & Co. raised their target price on Progyny from $17.00 to $23.00 and gave the stock a “neutral” rating in a research report on Tuesday, January 28th. Canaccord Genuity Group raised their price objective on Progyny from $17.00 to $23.00 and gave the stock a “hold” rating in a research report on Friday, February 28th. Finally, Bank of America upped their target price on Progyny from $21.00 to $25.00 and gave the company a “buy” rating in a report on Tuesday, February 11th. Nine research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $24.82.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.